June 2013 By Polly Clayden and Mark Harrington This chapter will discuss how to get the best drugs to the most people as quickly as possible; this requires that the compounds and combination products be: Discovered and developed in a…
This report is dedicated to Spencer Cox March 10, 1968–December 18, 2012 Walter Kurtz Photography © 2006 Remarks on the Naming of the Spencer Cox Center for Health Melanie Thompson, MD New York City, June 11, 2013 I am so…
July 2014 Back to basic science By Mike Frick The last year in tuberculosis (TB) vaccine research has demonstrated how setbacks can sometimes produce the potential for unexpected progress. Dominant hypotheses have yielded to new investigative directions, and unresolved questions…
July 2014 By Lindsay McKenna Introduction While the pediatric HIV drug pipeline has seen increased activity in recent years, the same cannot be said for pediatric TB. Adult-pediatric approval gaps remain an issue in HIV drug development, especially for children…
July 2014 By Erica Lessem Introduction After forty years without new approved drug classes, tuberculosis (TB) treatment has recently advanced with the approval of two new compounds to treat multidrug-resistant TB (MDR-TB): delamanid and bedaquiline.1,2,3 Yet with limited access to…
July 2014 By Colleen Daniels Accurate diagnosis of tuberculosis (TB) is the gateway to treatment and—it is hoped—cure for people with latent TB infection (LTBI) or active TB disease. According to the Stop TB Partnership and the World Health Organization…
By Karyn Kaplan and Tracy Swan How can governments and donors effectively address HCV if pharma refuses to drop drug prices? —Paata Sabelashvili, Activist, Georgian Harm Reduction Network Keeping up with the rapid pace of hepatitis C drug development,…
July 2014 By Tracy Swan Thanks to Jules Levin This update includes presentations from the American Association for the Study of Liver Diseases (AASLD) Meeting, the Conference on Retroviruses and Opportunistic Infections (CROI), the European Association for the Study of…
July 2014 By Tracy Swan BONANZA! The Gold Rush Is Under Way The direct-acting antiviral (DAA) era officially began in late 2013, with approval of the first all-oral treatment for hepatitis C virus (HCV) genotypes 2 and 3. A hefty…
July 2014 By Polly Clayden Since last year’s Pipeline Report, dolutegravir (DTG) was approved for children aged 12 years and older in the United States and Europe.1,2 The approvals for this age group were granted at the same time as…